1)Still GF:On a form of chronic joint disease in children. Med Chir Trans 80:47-60.9, 1897 PMID 20896907
2)Bywaters EG:Still's disease in the adult. Ann Rheum Dis 30:121-133, 1971 PMID 5315135
3)Asanuma YF, et al:Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 25:393-400, 2015 PMID 25382730
4)Maruyama A, et al:Clinical features of elderly-onset adult-onset Still's disease. Mod Rheumatol 31:862-868, 2021 PMID 32990106
5)Di Cola I, et al:Adult-onset Still's disease with elderly onset;Results from a multicentre study. Clin Exp Rheumatol 40:1517-1525, 2022 PMID 35579097
6)Yamamoto T:Cutaneous manifestations associated with adult-onset Still's disease;Important diagnostic values. Rheumatol Int 32:2233-2237, 2012 PMID 22198666
7)Pouchot J, et al:Adult Still's disease;Manifestations, disease course, and outcome in 62 patients. Medicine(Baltimore)70:118-136, 1991 PMID 2005777
8)Yamaguchi M, et al:Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424-430, 1992 PMID 1578458
9)Henter JI, et al:HLH-2004;Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124-131, 2007 PMID 16937360
10)Ravelli A, et al:2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis;A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 75:481-489, 2016 PMID 26865703
11)Tada Y, et al:Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease? Rheumatol Int 39:97-104, 2019 PMID 30051293
12)Feist E, et al:Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 14:603-618, 2018 PMID 30218025
13)Kaneko Y, et al:Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment;A randomised, double-blind, placebo-controlled phase Ⅲ trial. Ann Rheum Dis 77:1720-1729, 2018 PMID 30279267
14)Kobayashi M, et al:Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21:92-96, 2011 PMID 20737186